Open an account

Bolt Biotherapeutics

BOLT · NASDAQ

$4.31+$0.27 (+6.68%)TodayMarket closed ·
Prev close $4.04

About BOLT

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is headquartered in Redwood City, California and currently employs 23 full-time employees. The company went IPO on 2021-02-05. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The firm is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

Employees
23
Headquarters
Redwood City, California
Listed
Feb 5, 2021
Sector
Health Care
Industry
Biotechnology
Website
boltbio.com

BOLT key statistics

Market cap
8.30M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
20.24K
Volume
29.28K
Open price
$3.90
High today
$4.33
Low today
$4.05
52 Week high
$7.20
52 Week low
$3.10

Bolt Biotherapeutics (BOLT) at a glance

Bolt Biotherapeutics (BOLT) last traded at $4.31, with a market cap of 8.30M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.05 and $4.33. The current price is 6.4% above the day's low and 0.5% below its high.

Volume so far is 29.28K shares, above the average of 20.24K shares a day.

Over the past year Bolt Biotherapeutics has ranged from $3.10 to $7.20, and now sits 30% of the way up that range.

Bolt Biotherapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$4.57 per share against an estimate of -$3.45.

The average analyst price target is $6.12, 42.0% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $6.12
Low
$5.05
Now
$4.31
High
$7.35

BOLT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 26.2% on average.

  1. Q3 FY24: reported -$8.00 per share against an estimate of -$7.19
  2. Q4 FY24: reported -$7.60 per share against an estimate of -$7.75
  3. Q1 FY25: reported -$5.80 per share against an estimate of -$7.39
  4. Q2 FY25: reported -$4.46 per share against an estimate of -$6.58
  5. Q3 FY25: reported -$3.72 per share against an estimate of -$5.90
  6. Q4 FY25: reported -$3.84 per share against an estimate of -$6.23
  7. Q1 FY26: reported -$4.31 per share against an estimate of -$2.91
  8. Q2 FY26: reported -$4.57 per share against an estimate of -$3.45

BOLT news

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Press releasePRNewswire

    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT

  • Press releaseBusiness Wire

    BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

  • Press releasePRNewswire

    BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

  • Press releaseBusiness Wire

    BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

  • Press releasePRNewswire

    INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

  • Press releaseGlobe Newswire

    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm

Similar companies

Companies in the same industry as Bolt Biotherapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.